MSF call for cap for MDR-TB drug costs: only 180 people use delamanid over two years
MSF press release
On 24 February 2016, Médecins Sans Frontières (MSF) reported in a press release that more than two years after the approval of the new TB drug delamanid, only 180 people globally have used it, due to the high cost. 
Delamanid is one of only two new TB drug to be approved in the last 50 years, and is effective against multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB.
Delamanid needs to be taken with other drugs to treat drug-resistant TB. These regimens, without delamanid, cost between $1,000 – $4,500 per course at the lowest prices available to developing countries. Otsuka, the manufacturer of delamamid, said that it would charge some developing countries US $1,700 per treatment course. 
To date, Otsuka has registered delamanid in only four countries (Germany, Japan, South Korea, and the United Kingdom), none of which has a high burden of DR-TB.
MSF demand that the company register delamanid in high DR-TB burden countries and in countries where clinical trials for the drug took place.
To help with widespread scale up of DR-TB treatment, MSF is advocating for a target price of $500 per treatment course for drug-resistant TB.
Dr. Grania Brigden, TB Advisor for MSF’s Access Campaign said: “delamanid is neither affordable nor available in most countries today. The price […] needs to come down to an affordable level […] If people can’t access delamanid, this promising new drug will be effectively worthless.”
- MSF press release. Developing countries hit with high price for important new tuberculosis drug: More than two years after drug approved, only 180 people globally have received it
- DR-TB drug regimen prices are from the forthcoming MSF publication, DR-TB Drugs Under the Microscope, 4th Edition, March 2016.